{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:41Z","timestamp":1786986881460,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.clinthera.2020.01.023","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T18:26:50Z","timestamp":1583432810000},"page":"692-702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["An Update on Existing and Emerging Data for Meropenem-Vaborbactam"],"prefix":"10.1016","volume":"42","author":[{"given":"Bethany R.","family":"Shoulders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Casapao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Venugopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2020.01.023_bib1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1017\/ice.2018.304","article-title":"Re-estimating annual deaths due to multidrug-resistant organisms infections","volume":"40","author":"Burnham","year":"2019","journal-title":"Infect Control Hospit Epidemiol"},{"key":"10.1016\/j.clinthera.2020.01.023_bib3","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/CMR.00001-07","article-title":"Carbapenemases: the versatile \u03b2-lactamases","volume":"20","author":"Queenan","year":"2007","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl A","key":"10.1016\/j.clinthera.2020.01.023_bib4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jac\/24.suppl_A.85","article-title":"Bacteriostatic and bactericidal in-vitro activity of meropenem against clinical isolates, including Mycobacterium avium complex","volume":"24","author":"Inderlied","year":"1989","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"Suppl A","key":"10.1016\/j.clinthera.2020.01.023_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/24.suppl_A.31","article-title":"Comparative in-vitro activity of meropenem on clinical isolates from the United Kingdom","volume":"24","author":"King","year":"1989","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2020.01.023_bib6","series-title":"Merrem (Meropenem for Injection) Package Insert","year":"2019"},{"key":"10.1016\/j.clinthera.2020.01.023_bib7","series-title":"Vabomere (Meropenem; Vaborbactam) Package Insert","year":"2018"},{"key":"10.1016\/j.clinthera.2020.01.023_bib8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00003495-200868060-00006","article-title":"Meropenem: a review of its use in the treatment of serious bacterial infections","volume":"68","author":"Baldwin","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2020.01.023_bib9","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative review of the carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2020.01.023_bib10","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/jac\/dkv502","article-title":"Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study","volume":"71","author":"Guiterrez-Gutierrez","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2020.01.023_bib11","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","article-title":"Discovery of cyclic boronic acid \u03b2-lactamase inhibitor (RPX7009) with utility vs class A Serine Carbapenemases","volume":"58","author":"Hecker","year":"2015","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.clinthera.2020.01.023_bib12","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/jac\/dkt118","article-title":"Activity of biapenem (RPX2003) combined with the boronate \u03b2-Lactamase Inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae","volume":"68","author":"Livermore","year":"2013","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2020.01.023_bib13","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/phar.2210","article-title":"Pharmacokinetics and pharmacodynamics of \u03b2-lactamase inhibitors","volume":"39","author":"Crass","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2020.01.023_bib14","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/phar.2092","article-title":"Meropenem and vaborbactam: stepping up the battle against carbapenem-resistant Enterobacteriaceae","volume":"38","author":"Jorgensen","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2020.01.023_bib15","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.bmc.2007.10.075","article-title":"Structure-based optimization of cephalothin-analogue boronic acids as \u03b2-lactamase inhibitors","volume":"16","author":"Morandi","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.clinthera.2020.01.023_bib16","doi-asserted-by":"crossref","first-page":"7232","DOI":"10.1128\/AAC.01713-15","article-title":"Meropenem-RPX7009 concentrations in plasma, epithelial lining fluid, and alveolar macrophages of healthy adult subjects","volume":"59","author":"Wenzler","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2020.01.023_bib17","series-title":"Fortaz (Ceftazidime for Injection Single Vials) Package Insert","year":"2017"},{"key":"10.1016\/j.clinthera.2020.01.023_bib18","series-title":"Avycaz (Ceftazidime and Avibactam for Injection) Package Insert","year":"2019"},{"key":"10.1016\/j.clinthera.2020.01.023_bib19","series-title":"Primaxin (Imipenem and Cilastatin Solution for Injection) Package Insert","year":"2018"},{"key":"10.1016\/j.clinthera.2020.01.023_bib20","series-title":"Recarbrio (Imipenem; Cilastatin; Relebactam) Package Insert","year":"2019"},{"key":"10.1016\/j.clinthera.2020.01.023_bib21","article-title":"Phase 1 study of the safety, tolerability, and pharmacokinetics of vaborbactam and meropenem alone and in combination following single and multiple doses in healthy adult subjects","volume":"62","author":"Rubino","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2020.01.023_bib22","article-title":"Activity of simulated human dosage regimens of meropenem and vaborbactam against carbapenem-resistant Enterobacteriaceae in an in\u00a0vitro hollow-fiber model","volume":"62","author":"Sabet","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2020.01.023_bib23","series-title":"Ex\u00a0Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem-Vaborbactam","author":"Pandey","year":"2018"},{"key":"10.1016\/j.clinthera.2020.01.023_bib24","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1592\/phco.29.5.562","article-title":"Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis","volume":"29","author":"Heintz","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2020.01.023_bib25","doi-asserted-by":"crossref","first-page":"e01306","DOI":"10.1128\/AAC.01306-18","article-title":"Ex\u00a0vivo characterization of effects of renal replacement therapy modalities and settings on pharmacokinetics of meropenem and vaborbactam","volume":"62","author":"Sime","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2020.01.023_bib26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.clinthera.2017.12.007","article-title":"Physical compatibility of meropenem and vaborbactam with select intravenous drugs during simulated y-site administration","volume":"40","author":"Kidd","year":"2018","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2020.01.023_bib27","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1345\/aph.1E358","article-title":"Acute seizures due to a probable interaction between valproic acid and meropenem","volume":"39","author":"Coves-Orts","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2020.01.023_bib28","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1128\/AAC.00711-16","article-title":"Effect of the \u03b2-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae","volume":"60","author":"Castanheira","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2020.01.023_bib29","article-title":"Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae","volume":"6","author":"Lomovskaya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2020.01.023_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02048-18","article-title":"Effects of KPC variant and porin genotype on the in\u00a0vitro activity of meropenem-vaborbactam against carbapenem-resistant Enterobacteriaceae","volume":"63","author":"Wilson","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2020.01.023_bib31","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/JB.181.9.2726-2732.1999","article-title":"Identification and characterization of a new porin gene of Klebsiella pneumoniae: its role in beta-lactam antibiotic resistance","volume":"181","author":"Domenech-Sanchez","year":"1999","journal-title":"J\u00a0Bacteriol"},{"key":"10.1016\/j.clinthera.2020.01.023_bib32","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2217\/fmb.14.135","article-title":"Carbapenemase-producing Gram-negative bacteria: current epidemics, antimicrobial susceptibility and treatment options","volume":"10","author":"Jean","year":"2015","journal-title":"Future Microbiol"},{"key":"10.1016\/j.clinthera.2020.01.023_bib33","series-title":"Poster Presented at: ID Week","article-title":"Comparative in\u00a0vitro activity of meropenem\/vaborbactam and meropenem against a collection of real-world clinical isolates of Pseudomonas aeruginosa","author":"Patel","year":"2019"},{"key":"10.1016\/j.clinthera.2020.01.023_bib34","series-title":"Poster Presented at: ID Week","article-title":"Meropenem (MV) in\u00a0vitro activity against carbapenem-resistant Klebsiella pneumoniae (CRKP) isolates with outer membrane porin gene mutations","author":"Yasmin","year":"2019"},{"key":"10.1016\/j.clinthera.2020.01.023_bib35","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/j.bmcl.2019.05.031","article-title":"Profiling interactions of vaborbactam with metallo-\u03b2-Lactamases","volume":"29","author":"Langley","year":"2019","journal-title":"Biorg Med Chem Lett"},{"key":"10.1016\/j.clinthera.2020.01.023_bib36","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1093\/jac\/dkw028","article-title":"Inactivation or inhibition of AcrAB-TolC increases resistance of carbapenemase-producing Enterobacteriaceae to carbapenems","volume":"71","author":"Saw","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2020.01.023_bib37","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01426-19","article-title":"Searching for the optimal treatment for metallo- and serine-\u03b2-lactamase producing Enterobacteriaceae: aztreonam in combination with ceftazidime-avibactam or meropenem-vaborbactam","author":"Biagi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2020.01.023_bib38","article-title":"In\u00a0Vitro activity of the new \u03b2-lactamase inhibitors relebactam and vaborbactam in combination with \u03b2-lactams against Mycobacterium abscessus complex clinical isolates","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2020.01.023_bib39","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem-vaborbactam vs. piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infections: the TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2020.01.023_bib40","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized controlled trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.clinthera.2020.01.023_bib41","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s12325-019-00981-y","article-title":"Efficacy and safety of meropenem-vaborbactam versus best-available therapy for the treatment of carbapenem-resistant\u00a0Enterobacteriaceae infections in patient without prior\u00a0antimicrobial failure: a post\u00a0hoc\u00a0analysis","volume":"36","author":"Bassetti","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2020.01.023_bib42","series-title":"Poster Presented at: ID Week","article-title":"Real-world experience with meropenem-vaborbactam (M\/V) for treatment of carbapenem-resistant Enterobactericeae (CRE) Infections","author":"Shields","year":"2019"},{"key":"10.1016\/j.clinthera.2020.01.023_bib43","series-title":"Poster Presented at: ID Week","article-title":"Recurrence of infection and emergence of drug resistance after treatment with meropenem\/vaborbactam compared to ceftazidime\/avibactam in carbapenem-resistant Enterobacteriaceae infections","author":"Ackley","year":"2019"},{"key":"10.1016\/j.clinthera.2020.01.023_bib44","author":"Bethesda (MD): National Library of Medicine (Us)"},{"key":"10.1016\/j.clinthera.2020.01.023_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01551-18","article-title":"Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-resistant Klebsiella pneumoniae bacteremia and abscess in a liver transplant recipient","volume":"63","author":"Athans","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2020.01.023_bib46","first-page":"3529","article-title":"Averting the post-antibiotic era: successful use of meropenem-vaborbactam for carbapenem-resistant Serratia marcescens and Enterobacter aerogenes bacteremia in a hemodialysis patient","volume":"73","author":"Jorgensen","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2020.01.023_bib47","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.diagmicrobio.2018.09.017","article-title":"In\u00a0vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance","volume":"93","author":"Kinn","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"10","key":"10.1016\/j.clinthera.2020.01.023_bib48","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01076-18","article-title":"Past and present perspective on \u03b2-lactamases","volume":"62","author":"Bush","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2020.01.023_bib49","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.sjbs.2014.08.002","article-title":"Antibiotic resistance and extended-spectrum beta-lactamases: types, epidemiology, and treatment","volume":"22","author":"Shaikh","year":"2015","journal-title":"Saudi J Biol Sci"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182030062X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182030062X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:52:45Z","timestamp":1758963165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929182030062X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S014929182030062X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.01.023","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Update on Existing and Emerging Data for Meropenem-Vaborbactam","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2020.01.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}